Skip to main content

Table 5 MMRM and LOCF_ANCOVA analyses of HAMD17 total score in Studies 1 and 2.

From: The efficacy of duloxetine: A comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials

  

STUDY 1

STUDY 2

MMRM

THERAPY

Week

N

Mean change

Std.error

p-value

N

Mean change

Std.error

p-value

DULOX

1

121

-2.89

0.36

.435

123

-2.89

0.38

.601

PLACEBO

1

115

-2.50

0.37

 

136

-2.64

0.36

 

DULOX

2

112

-5.72

0.49

< .001

109

-5.54

0.48

.071

PLACEBO

2

110

-3.39

0.50

 

129

-4.43

0.45

 

DULOX

3

105

-7.37

0.53

< .001

108

-6.82

0.55

.287

PLACEBO

3

103

-4.58

0.54

 

122

-6.06

0.52

 

DULOX

5

100

-8.76

0.60

< .001

98

-8.58

0.66

.116

PLACEBO

5

101

-5.74

0.60

 

111

-7.20

0.62

 

DULOX

7

91

-9.93

0.64

< .001

89

-10.14

0.69

.008

PLACEBO

7

93

-5.82

0.65

 

97

-7.69

0.65

 

DULOX

9

84

-10.91

0.70

< .001

81

-10.46

0.71

.024

PLACEBO

9

89

-6.05

0.69

 

90

-8.29

0.67

 

LOCF_ANCOVA

DULOX

LOCF_ANCOVA

121

-9.47

0.63

< .001

123

-8.75

0.71

.048

PLACEBO

LOCF_ANCOVA

115

-5.67

0.66

 

136

-7.02

0.68

 
Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us